



CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
<u>January 28, 2002</u> Date	<u>Gina N. Shishima</u>

RECEIVED
FEB 28 2002
TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Yu

Serial No.: 09/841,720

Filed: April 24, 2001

For: MU OPIOID RECEPTOR METHODS (as amended)

Group Art Unit: 1647

Examiner: Unknown

Atty. Dkt. No.: INDA:002USD1

**STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.825(a) AND (b)
AND STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(g)**

BOX SEQUENCE


Commissioner for Patents
Washington, D.C. 20231

Commissioner:

Submitted herewith is a substitute computer readable form and a substitute paper copy of the sequence listing of those sequences in the captioned patent application, wherein minor errors have been corrected. The substitute computer readable form of the sequence listing is the same as the substitute paper copy of the sequence listing. The sequence information provided in the Specification is also the same as the sequence listing of the enclosed substitute computer readable and paper forms of the sequence listing.

In accordance with 37 C.F.R. § 1.821(g), it is herewith represented that no new matter is included with this submission.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201
(512) 536-4598 (facsimile)

Date: January 28, 2002



SEQUENCE LISTING

RECEIVED #8
FEB 28 2002
TECH CENTER 1600/2900

<110> YU, LEI

<120> MU OPIOID RECEPTOR: COMPOSITIONS AND METHODS

<130> INDA:002USD1

<140> 09/841,720

<141> 2001-04-24

<150> 08/120,601

<151> 1993-09-13

<160> 9

<170> PatentIn Ver. 2.1

<210> 1

<211> 1618

<212> DNA

<213> RAT

<220>

<221> CDS

<222> (214) .. (1407)

<400> 1

cgtggaaggg ggctacaagc agaggagaat atcagacgct cagacgttcc cttctgcctg 60

ccgctcttct ctggttcac tagggctggg ccatgtaaga atctgacgga gcctagggca 120

gctgtgagag gaagaggctg gggcgctgg aaccgaaaa gtctgagtgc tctcagttac 180

agcctaccta gtccgcagca ggccttcagc acc atg gac agc agc acc ggc cca 234

Met Asp Ser Ser Thr Gly Pro

1

5

ggg aac acc agc gac tgc tca gac ccc tta gct cag gca agt tgc tcc 282

Gly Asn Thr Ser Asp Cys Ser Asp Pro Leu Ala Gln Ala Ser Cys Ser

10

15

20

cca gca cct ggc tcc tgg ctc aac ttg tcc cac gtt gat ggc aac cag 330

Pro Ala Pro Gly Ser Trp Leu Asn Leu Ser His Val Asp Gly Asn Gln

25

30

35

tcc gat cca tgc ggt ctg aac cgc acc ggg ctt ggc ggg aac gac agc 378

Ser Asp Pro Cys Gly Leu Asn Arg Thr Gly Leu Gly Gly Asn Asp Ser

40

45

50

55

ctg tgc cct cag acc ggc agc cct tcc atg gtc aca gcc att acc atc 426

Leu Cys Pro Gln Thr Gly Ser Pro Ser Met Val Thr Ala Ile Thr Ile

60

65

70

atg gcc ctc tac tct atc gtg tgt gta gtg ggc ctc ttc gga aac ttc 474

Met	Ala	Leu	Tyr	Ser	Ile	Val	Cys	Val	Val	Gly	Leu	Phe	Gly	Asn	Phe		
			75					80					85				
ctg	gtc	atg	tat	gtg	att	gta	aga	tac	acc	aaa	atg	aag	act	gcc	acc	522	
Leu	Val	Met	Tyr	Val	Ile	Val	Arg	Tyr	Thr	Lys	Met	Lys	Thr	Ala	Thr		
		90					95					100					
aac	atc	tac	att	ttc	aac	ctt	gct	ctg	gca	gac	gcc	tta	gcg	acc	agt	570	
Asn	Ile	Tyr	Ile	Phe	Asn	Leu	Ala	Leu	Ala	Asp	Ala	Leu	Ala	Thr	Ser		
	105					110					115						
aca	ctg	ccc	ttt	cag	agt	gtc	aac	tac	ctg	atg	gga	aca	tgg	ccc	ttc	618	
Thr	Leu	Pro	Phe	Gln	Ser	Val	Asn	Tyr	Leu	Met	Gly	Thr	Trp	Pro	Phe		
	120				125					130					135		
gga	acc	atc	ctc	tgc	aag	atc	gtg	atc	tca	ata	gat	tac	tac	aac	atg	666	
Gly	Thr	Ile	Leu	Cys	Lys	Ile	Val	Ile	Ser	Ile	Asp	Tyr	Tyr	Asn	Met		
				140					145					150			
ttc	acc	agc	ata	ttc	acc	ctc	tgc	acc	atg	agc	gtg	gac	cgc	tac	att	714	
Phe	Thr	Ser	Ile	Phe	Thr	Leu	Cys	Thr	Met	Ser	Val	Asp	Arg	Tyr	Ile		
		155					160					165					
gct	gtc	tgc	cac	cca	gtc	aaa	gcc	ctg	gat	ttc	cgt	acc	ccc	cga	aat	762	
Ala	Val	Cys	His	Pro	Val	Lys	Ala	Leu	Asp	Phe	Arg	Thr	Pro	Arg	Asn		
		170				175						180					
gcc	aaa	atc	gtc	aac	gtc	tgc	aac	tgg	atc	ctc	tct	tct	gcc	atc	ggc	810	
Ala	Lys	Ile	Val	Asn	Val	Cys	Asn	Trp	Ile	Leu	Ser	Ser	Ala	Ile	Gly		
	185					190					195						
ctg	cct	gta	atg	ttc	atg	gca	acc	aca	aaa	tac	agg	cag	ggg	tcc	ata	858	
Leu	Pro	Val	Met	Phe	Met	Ala	Thr	Thr	Lys	Tyr	Arg	Gln	Gly	Ser	Ile		
	200				205					210					215		
gat	tgc	acc	ctc	acg	ttc	tcc	cac	cca	acc	tgg	tac	tgg	gag	aac	ctg	906	
Asp	Cys	Thr	Leu	Thr	Phe	Ser	His	Pro	Thr	Trp	Tyr	Trp	Glu	Asn	Leu		
				220				225						230			
ctc	aaa	atc	tgt	gtc	ttt	atc	ttc	gct	ttc	atc	atg	ccg	atc	ctc	atc	954	
Leu	Lys	Ile	Cys	Val	Phe	Ile	Phe	Ala	Phe	Ile	Met	Pro	Ile	Leu	Ile		
		235						240					245				
atc	act	gtg	tgt	tac	ggc	ctg	atg	atc	tta	cga	ctc	aag	agc	gtt	cgc	1002	
Ile	Thr	Val	Cys	Tyr	Gly	Leu	Met	Ile	Leu	Arg	Leu	Lys	Ser	Val	Arg		
		250					255					260					
atg	cta	tgc	ggc	tcc	aaa	gaa	aag	gac	agg	aat	ctg	cgc	agg	atc	acc	1050	
Met	Leu	Ser	Gly	Ser	Lys	Glu	Lys	Asp	Arg	Asn	Leu	Arg	Arg	Ile	Thr		
	265					270					275						
cgg	atg	gtg	ctg	gtg	gtc	gtg	gct	gta	ttt	atc	gtc	tgc	tgg	acc	ccc	1098	
Arg	Met	Val	Leu	Val	Val	Val	Ala	Val	Phe	Ile	Val	Cys	Trp	Thr	Pro		
	280				285					290					295		

atc cac atc tac gtc atc atc aaa gcg ctg atc acg att cca gaa acc 1146
 Ile His Ile Tyr Val Ile Ile Lys Ala Leu Ile Thr Ile Pro Glu Thr
 300 305 310

aca ttt cag acc gtt tcc tgg cac ttc tgc att gct ttg ggt tac acg 1194
 Thr Phe Gln Thr Val Ser Trp His Phe Cys Ile Ala Leu Gly Tyr Thr
 315 320 325

aac agc tgc ctg aat cca gtt ctt tac gcc ttc ctg gat gaa aac ttc 1242
 Asn Ser Cys Leu Asn Pro Val Leu Tyr Ala Phe Leu Asp Glu Asn Phe
 330 335 340

aag cga tgc ttc aga gag ttc tgc atc cca acc tcg tcc acg atc gaa 1290
 Lys Arg Cys Phe Arg Glu Phe Cys Ile Pro Thr Ser Ser Thr Ile Glu
 345 350 355

cag caa aac tcc act cga gtc cgt cag aac act agg gaa cat ccc tcc 1338
 Gln Gln Asn Ser Thr Arg Val Arg Gln Asn Thr Arg Glu His Pro Ser
 360 365 370 375

acg gct aat aca gtg gat cga act aac cac cag cta gaa aat ctg gag 1386
 Thr Ala Asn Thr Val Asp Arg Thr Asn His Gln Leu Glu Asn Leu Glu
 380 385 390

gca gaa act gct cca ttg ccc taactgggtc tcacaccatc cagaccctcg 1437
 Ala Glu Thr Ala Pro Leu Pro
 395

ctaagcttag aggccgccat ctacgtggaa tcaggttgct gtcaggggtgt gtgggaggct 1497

ctggtttccct gagaaacccat ctgatcctgc attcaaagtc attcctctct ggctacttca 1557

ctctgcacat gagagatgct cagactgata aagaccagaa gaaagaagag actaccggac 1617

a 1618

<210> 2
 <211> 398
 <212> PRT
 <213> RAT

<400> 2
 Met Asp Ser Ser Thr Gly Pro Gly Asn Thr Ser Asp Cys Ser Asp Pro
 1 5 10 15

Leu Ala Gln Ala Ser Cys Ser Pro Ala Pro Gly Ser Trp Leu Asn Leu
 20 25 30

Ser His Val Asp Gly Asn Gln Ser Asp Pro Cys Gly Leu Asn Arg Thr
 35 40 45

Gly Leu Gly Gly Asn Asp Ser Leu Cys Pro Gln Thr Gly Ser Pro Ser
 50 55 60

Met	Val	Thr	Ala	Ile	Thr	Ile	Met	Ala	Leu	Tyr	Ser	Ile	Val	Cys	Val	65	70	75	80
Val	Gly	Leu	Phe	Gly	Asn	Phe	Leu	Val	Met	Tyr	Val	Ile	Val	Arg	Tyr	85	90	95	
Thr	Lys	Met	Lys	Thr	Ala	Thr	Asn	Ile	Tyr	Ile	Phe	Asn	Leu	Ala	Leu	100	105	110	
Ala	Asp	Ala	Leu	Ala	Thr	Ser	Thr	Leu	Pro	Phe	Gln	Ser	Val	Asn	Tyr	115	120	125	
Leu	Met	Gly	Thr	Trp	Pro	Phe	Gly	Thr	Ile	Leu	Cys	Lys	Ile	Val	Ile	130	135	140	
Ser	Ile	Asp	Tyr	Tyr	Asn	Met	Phe	Thr	Ser	Ile	Phe	Thr	Leu	Cys	Thr	145	150	155	160
Met	Ser	Val	Asp	Arg	Tyr	Ile	Ala	Val	Cys	His	Pro	Val	Lys	Ala	Leu	165	170	175	
Asp	Phe	Arg	Thr	Pro	Arg	Asn	Ala	Lys	Ile	Val	Asn	Val	Cys	Asn	Trp	180	185	190	
Ile	Leu	Ser	Ser	Ala	Ile	Gly	Leu	Pro	Val	Met	Phe	Met	Ala	Thr	Thr	195	200	205	
Lys	Tyr	Arg	Gln	Gly	Ser	Ile	Asp	Cys	Thr	Leu	Thr	Phe	Ser	His	Pro	210	215	220	
Thr	Trp	Tyr	Trp	Glu	Asn	Leu	Leu	Lys	Ile	Cys	Val	Phe	Ile	Phe	Ala	225	230	235	240
Phe	Ile	Met	Pro	Ile	Leu	Ile	Ile	Thr	Val	Cys	Tyr	Gly	Leu	Met	Ile	245	250	255	
Leu	Arg	Leu	Lys	Ser	Val	Arg	Met	Leu	Ser	Gly	Ser	Lys	Glu	Lys	Asp	260	265	270	
Arg	Asn	Leu	Arg	Arg	Ile	Thr	Arg	Met	Val	Leu	Val	Val	Val	Ala	Val	275	280	285	
Phe	Ile	Val	Cys	Trp	Thr	Pro	Ile	His	Ile	Tyr	Val	Ile	Ile	Lys	Ala	290	295	300	
Leu	Ile	Thr	Ile	Pro	Glu	Thr	Thr	Phe	Gln	Thr	Val	Ser	Trp	His	Phe	305	310	315	320
Cys	Ile	Ala	Leu	Gly	Tyr	Thr	Asn	Ser	Cys	Leu	Asn	Pro	Val	Leu	Tyr	325	330	335	
Ala	Phe	Leu	Asp	Glu	Asn	Phe	Lys	Arg	Cys	Phe	Arg	Glu	Phe	Cys	Ile	340	345	350	
Pro	Thr	Ser	Ser	Thr	Ile	Glu	Gln	Gln	Asn	Ser	Thr	Arg	Val	Arg	Gln				

355	360	365
Asn Thr Arg Glu His Pro Ser Thr Ala Asn Thr Val Asp Arg Thr Asn		
370	375	380

His Gln Leu Glu Asn Leu Glu Ala Glu Thr Ala Pro Leu Pro
385 390 395

<210> 3
 <211> 1618
 <212> DNA
 <213> RAT

<220>
 <221> CDS
 <222> (339) .. (1232)

<400> 3
 cgtggaaggg ggctacaagc agaggagaat atcagacgct cagacgttcc cttctgcctg 60
 ccgctcttct ctggttccac tagggctggg ccatgtaaga atctgacgga gcctagggca 120
 gctgtgagag gaagaggctg gggcgcgctgg aaccgaaaa gtctgagtgc tctcagttac 180
 agcctaccta gtccgcagca ggccttcagc accatggaca gcagcaccgg cccagggaaac 240
 accagcgact gctcagaccc cttagctcag gcaagttgct cccagcacc tggctcctgg 300
 ctcaacttgt cccacgttga tggcaaccag tccgatcc atg cgg tct gaa ccg cac 356
 Met Arg Ser Glu Pro His
 1 5

cgg gct tgg cgg gaa cga cag cct gtg ccc tca gac cgg cag ccc ttc	404
Arg Ala Trp Arg Glu Arg Gln Pro Val Pro Ser Asp Arg Gln Pro Phe	
10 15 20	

cat ggt cac agc cat tac cat cat ggc cct cta ctc tat cgt gtg tgt	452
His Gly His Ser His Tyr His His Gly Pro Leu Leu Tyr Arg Val Cys	
25 30 35	

agt ggg cct ctt cgg aaa ctt cct ggt cat gta tgt gat tgt aag ata	500
Ser Gly Pro Leu Arg Lys Leu Pro Gly His Val Cys Asp Cys Lys Ile	
40 45 50	

cac caa aat gaa gac tgc cac caa cat cta cat ttt caa cct tgc tct	548
His Gln Asn Glu Asp Cys His Gln His Leu His Phe Gln Pro Cys Ser	
55 60 65 70	

ggc aga cgc ctt agc gac cag tac act gcc ctt tca gag tgt caa cta	596
Gly Arg Arg Leu Ser Asp Gln Tyr Thr Ala Leu Ser Glu Cys Gln Leu	
75 80 85	

cct gat ggg aac atg gcc ctt cgg aac cat cct ctg caa gat cgt gat	644
---	-----

Pro Asp Gly Asn Met Ala Leu Arg Asn His Pro Leu Gln Asp Arg Asp	
90 95 100	
ctc aat aga tta cta caa cat gtt cac cag cat att cac cct ctg cac	692
Leu Asn Arg Leu Leu Gln His Val His Gln His Ile His Pro Leu His	
105 110 115	
cat gag cgt gga ccg cta cat tgc tgt ctg cca ccc agt caa agc cct	740
His Glu Arg Gly Pro Leu His Cys Cys Leu Pro Pro Ser Gln Ser Pro	
120 125 130	
gga ttt ccg tac ccc ccg aaa tgc caa aat cgt caa cgt ctg caa ctg	788
Gly Phe Pro Tyr Pro Pro Lys Cys Gln Asn Arg Gln Arg Leu Gln Leu	
135 140 145 150	
gat cct ctc ttc tgc cat cgg tct gcc tgt aat gtt cat ggc aac cac	836
Asp Pro Leu Phe Cys His Arg Ser Ala Cys Asn Val His Gly Asn His	
155 160 165	
aaa ata cag gca ggg gtc cat aga ttg cac cct cac gtt ctc cca ccc	884
Lys Ile Gln Ala Gly Val His Arg Leu His Pro His Val Leu Pro Pro	
170 175 180	
aac ctg gta ctg gga gaa cct gct caa aat ctg tgt ctt tat ctt cgc	932
Asn Leu Val Leu Gly Glu Pro Ala Gln Asn Leu Cys Leu Tyr Leu Arg	
185 190 195	
ttt cat cat gcc gat cct cat cat cac tgt gtg tta cgg cct gat gat	980
Phe His His Ala Asp Pro His His His Cys Val Leu Arg Pro Asp Asp	
200 205 210	
ctt acg act caa gag cgt tgc cat gct atc ggg ctc caa aga aaa gga	1028
Leu Thr Thr Gln Glu Arg Ser His Ala Ile Gly Leu Gln Arg Lys Gly	
215 220 225 230	
cag gaa tct gcg cag gat cac ccg gat ggt gct ggt ggt cgt ggc tgt	1076
Gln Glu Ser Ala Gln Asp His Pro Asp Gly Ala Gly Gly Arg Gly Cys	
235 240 245	
att tat cgt ctg ctg gac ccc cat cca cat cta cgt cat cat caa agc	1124
Ile Tyr Arg Leu Leu Asp Pro His Pro His Leu Arg His His Gln Ser	
250 255 260	
gct gat cac gat tcc aga aac cac att tca gac cgt ttc ctg gca ctt	1172
Ala Asp His Asp Ser Arg Asn His Ile Ser Asp Arg Phe Leu Ala Leu	
265 270 275	
ctg cat tgc ttt ggg tta cac gaa cag ctg cct gaa tcc agt tct tta	1220
Leu His Cys Phe Gly Leu His Glu Gln Leu Pro Glu Ser Ser Ser Leu	
280 285 290	
cgc ctt cct gga tgaaaacttc aagcgatgct tcagagagtt ctgcatccca	1272
Arg Leu Pro Gly	
295	

acctcgcca cgatcgaaca gcaaaactcc actcgagtcc gtcagaacac tagggaacat 1332
 ccctccacgg ctaatacagt ggatcgaact aaccaccagc tagaaaatct ggaggcagaa 1392
 actgctccat tgcctaact gggcttcaca ccatccagac cctcgctaag cctagaggcc 1452
 gccatctacg tggaatcagg ttgctgtcag ggtgtgtggg aggctctggg ttcctgagaa 1512
 accatctgat cctgcattca aagtcattcc tctctggcta cttcactctg cacatgagag 1572
 atgctcagac tgatcaagac cagaagaaag aagagactac cggaca 1618

<210> 4
 <211> 298
 <212> PRT
 <213> RAT

<400> 4
 Met Arg Ser Glu Pro His Arg Ala Trp Arg Glu Arg Gln Pro Val Pro
 1 5 10 15
 Ser Asp Arg Gln Pro Phe His Gly His Ser His Tyr His His Gly Pro
 20 25 30
 Leu Leu Tyr Arg Val Cys Ser Gly Pro Leu Arg Lys Leu Pro Gly His
 35 40 45
 Val Cys Asp Cys Lys Ile His Gln Asn Glu Asp Cys His Gln His Leu
 50 55 60
 His Phe Gln Pro Cys Ser Gly Arg Arg Leu Ser Asp Gln Tyr Thr Ala
 65 70 75 80
 Leu Ser Glu Cys Gln Leu Pro Asp Gly Asn Met Ala Leu Arg Asn His
 85 90 95
 Pro Leu Gln Asp Arg Asp Leu Asn Arg Leu Leu Gln His Val His Gln
 100 105 110
 His Ile His Pro Leu His His Glu Arg Gly Pro Leu His Cys Cys Leu
 115 120 125
 Pro Pro Ser Gln Ser Pro Gly Phe Pro Tyr Pro Pro Lys Cys Gln Asn
 130 135 140
 Arg Gln Arg Leu Gln Leu Asp Pro Leu Phe Cys His Arg Ser Ala Cys
 145 150 155 160
 Asn Val His Gly Asn His Lys Ile Gln Ala Gly Val His Arg Leu His
 165 170 175
 Pro His Val Leu Pro Pro Asn Leu Val Leu Gly Glu Pro Ala Gln Asn
 180 185 190

Leu Cys Leu Tyr Leu Arg Phe His His Ala Asp Pro His His His Cys
 195 200 205

Val Leu Arg Pro Asp Asp Leu Thr Thr Gln Glu Arg Ser His Ala Ile
 210 215 220

Gly Leu Gln Arg Lys Gly Gln Glu Ser Ala Gln Asp His Pro Asp Gly
 225 230 235 240

Ala Gly Gly Arg Gly Cys Ile Tyr Arg Leu Leu Asp Pro His Pro His
 245 250 255

Leu Arg His His Gln Ser Ala Asp His Asp Ser Arg Asn His Ile Ser
 260 265 270

Asp Arg Phe Leu Ala Leu Leu His Cys Phe Gly Leu His Glu Gln Leu
 275 280 285

Pro Glu Ser Ser Ser Leu Arg Leu Pro Gly
 290 295

<210> 5
 <211> 21
 <212> DNA
 <213> Mus musculus

<400> 5
 atcttcaccc tcaccatgat g 21

<210> 6
 <211> 20
 <212> DNA
 <213> Mus musculus

<400> 6
 cggtccttct ccttggaacc 20

<210> 7
 <211> 372
 <212> PRT
 <213> Mus musculus

<400> 7
 Met Glu Leu Val Pro Ser Ala Arg Ala Glu Leu Gln Ser Ser Pro Leu
 1 5 10 15

Val Asn Leu Ser Asp Ala Phe Pro Ser Ala Phe Pro Ser Ala Gly Ala
 20 25 30

Asn Ala Leu Gly Ser Pro Gly Ala Arg Ser Ala Ser Met Leu Ala Leu
 35 40 45

Ala	Ile	Ala	Ile	Thr	Ala	Leu	Tyr	Ser	Ala	Val	Cys	Ala	Val	Gly	Leu	50	55	60
Leu	Gly	Asn	Val	Leu	Val	Met	Phe	Gly	Ile	Val	Arg	Tyr	Thr	Lys	Leu	65	70	75
Lys	Thr	Ala	Thr	Asn	Ile	Tyr	Ile	Phe	Asn	Leu	Ala	Leu	Ala	Asp	Ala	85	90	95
Leu	Ala	Thr	Ser	Thr	Leu	Pro	Phe	Gln	Ser	Val	Asn	Tyr	Leu	Met	Glu	100	105	110
Thr	Trp	Pro	Phe	Gly	Glu	Leu	Leu	Cys	Lys	Ala	Val	Leu	Ser	Ile	Asp	115	120	125
Tyr	Tyr	Asn	Met	Phe	Thr	Ser	Ile	Phe	Thr	Leu	Thr	Met	Met	Ser	Val	130	135	140
Asp	Arg	Tyr	Ile	Ala	Val	Cys	His	Pro	Val	Lys	Ala	Leu	Asp	Phe	Arg	145	150	155
Thr	Pro	Ala	Lys	Ala	Lys	Leu	Ile	Asn	Ile	Cys	Ile	Trp	Val	Leu	Ala	165	170	175
Ser	Gly	Val	Gly	Val	Pro	Ile	Met	Val	Met	Ala	Val	Thr	Gln	Pro	Arg	180	185	190
Asp	Gly	Ala	Val	Val	Cys	Met	Leu	Gln	Phe	Pro	Ser	Pro	Ser	Trp	Tyr	195	200	205
Trp	Asp	Thr	Val	Thr	Lys	Ile	Cys	Val	Phe	Ile	Phe	Ala	Phe	Val	Val	210	215	220
Pro	Ile	Leu	Ile	Ile	Thr	Val	Cys	Tyr	Gly	Leu	Met	Leu	Leu	Arg	Leu	225	230	235
Arg	Ser	Val	Arg	Leu	Leu	Ser	Gly	Ser	Lys	Glu	Lys	Asp	Arg	Ser	Leu	245	250	255
Arg	Arg	Ile	Thr	Arg	Met	Val	Leu	Val	Val	Val	Gly	Ala	Phe	Val	Val	260	265	270
Cys	Trp	Ala	Pro	Ile	His	Ile	Phe	Val	Ile	Val	Trp	Thr	Leu	Val	Asp	275	280	285
Ile	Asn	Arg	Arg	Asp	Pro	Leu	Val	Val	Ala	Ala	Leu	His	Leu	Cys	Ile	290	295	300
Ala	Leu	Gly	Tyr	Ala	Asn	Ser	Ser	Leu	Asn	Pro	Val	Leu	Tyr	Ala	Phe	305	310	315
Leu	Asp	Glu	Asn	Phe	Lys	Arg	Cys	Phe	Arg	Gln	Leu	Cys	Arg	Thr	Pro	325	330	335

Cys Gly Arg Gln Glu Pro Gly Ser Leu Arg Arg Pro Arg Gln Ala Thr
 340 345 350

Thr Arg Glu Arg Val Thr Ala Cys Thr Pro Ser Asp Gly Pro Gly Gly
 355 360 365

Gly Ala Ala Ala
 370

<210> 8
 <211> 391
 <212> PRT
 <213> RAT

<400> 8
 Met Phe Pro Asn Gly Thr Ala Pro Ser Pro Thr Ser Ser Pro Ser Ser
 1 5 10 15

Ser Pro Gly Gly Cys Gly Glu Gly Leu Cys Ser Arg Gly Pro Gly Ser
 20 25 30

Gly Ala Ala Asp Gly Met Glu Glu Pro Gly Arg Asn Leu Ser Gln Asn
 35 40 45

Gly Thr Leu Ser Glu Gly Gln Gly Ser Ala Ile Leu Ile Ser Phe Ile
 50 55 60

Tyr Ser Val Val Cys Leu Val Gly Leu Cys Gly Asn Ser Met Val Ile
 65 70 75 80

Tyr Val Ile Leu Arg Tyr Ala Lys Met Lys Thr Ala Thr Asn Ile Tyr
 85 90 95

Ile Leu Asn Leu Ala Ile Ala Asp Glu Leu Leu Met Leu Ser Val Pro
 100 105 110

Phe Leu Val Thr Ser Thr Leu Leu Arg His Trp Pro Phe Gly Ala Leu
 115 120 125

Leu Cys Arg Leu Val Leu Ser Val Asp Ala Tyr Asn Met Phe Thr Ser
 130 135 140

Ile Tyr Cys Leu Thr Val Leu Ser Val Asp Arg Tyr Val Ala Val Val
 145 150 155 160

His Pro Ile Lys Ala Ala Arg Tyr Arg Arg Pro Thr Val Ala Lys Val
 165 170 175

Val Asn Leu Gly Val Trp Val Leu Ser Leu Leu Val Ile Leu Pro Ile
 180 185 190

Val Val Phe Ser Arg Thr Ala Ala Asn Ser Asp Gly Thr Val Ala Cys
 195 200 205

Asn Met Leu Met Pro Glu Pro Ala Gln Arg Trp Leu Val Gly Phe Val
210 215 220

Leu Tyr Thr Phe Leu Met Gly Phe Leu Leu Pro Val Gly Ala Ile Cys
225 230 235 240

Leu Cys Tyr Val Leu Ile Ile Ala Lys Met Arg Met Val Ala Leu Lys
245 250 255

Ala Gly Trp Gln Gln Arg Lys Arg Ser Glu Arg Lys Ile Thr Leu Met
260 265 270

Val Met Met Val Val Met Val Phe Val Ile Cys Trp Met Pro Phe Tyr
275 280 285

Val Val Gln Leu Val Asn Val Phe Ala Glu Gln Asp Asp Ala Thr Val
290 295 300

Ser Gln Leu Ser Val Ile Leu Gly Tyr Ala Asn Ser Cys Ala Asn Pro
305 310 315 320

Ile Leu Tyr Gly Phe Leu Ser Asp Asn Phe Lys Arg Ser Phe Gln Arg
325 330 335

Ile Leu Cys Leu Ser Trp Met Asp Asn Ala Ala Glu Glu Pro Val Asp
340 345 350

Tyr Tyr Ala Thr Ala Leu Lys Ser Arg Ala Tyr Ser Val Glu Asp Phe
355 360 365

Gln Pro Glu Asn Leu Glu Ser Gly Gly Val Phe Arg Asn Gly Thr Cys
370 375 380

Ala Ser Arg Ile Ser Thr Leu
385 390

<210> 9
<211> 369
<212> PRT
<213> RAT

<400> 9
Met Glu Leu Thr Ser Glu Gln Phe Asn Gly Ser Gln Val Trp Ile Pro
1 5 10 15

Ser Pro Phe Asp Leu Asn Gly Ser Leu Gly Pro Ser Asn Gly Ser Asn
20 25 30

Gln Thr Glu Pro Tyr Tyr Asp Met Thr Ser Asn Ala Val Leu Thr Phe
35 40 45

Ile Tyr Phe Val Val Cys Val Val Gly Leu Cys Gly Asn Thr Leu Val
50 55 60

Ile	Tyr	Val	Ile	Leu	Arg	Tyr	Ala	Lys	Met	Lys	Thr	Ile	Thr	Asn	Ile	
65					70					75					80	
Tyr	Ile	Leu	Asn	Leu	Ala	Ile	Ala	Asp	Glu	Leu	Phe	Met	Leu	Gly	Leu	
			85						90					95		
Pro	Phe	Leu	Ala	Met	Gln	Val	Ala	Leu	Val	His	Trp	Pro	Phe	Gly	Lys	
			100					105						110		
Ala	Ile	Cys	Arg	Val	Val	Met	Thr	Val	Asp	Gly	Ile	Asn	Gln	Phe	Thr	
			115				120					125				
Ser	Ile	Phe	Cys	Leu	Thr	Val	Met	Ser	Ile	Asp	Arg	Tyr	Leu	Ala	Val	
			130				135				140					
Val	His	Pro	Ile	Lys	Ser	Ala	Lys	Trp	Arg	Arg	Pro	Arg	Thr	Ala	Lys	
145					150					155					160	
Met	Ile	Asn	Val	Ala	Val	Trp	Gly	Val	Ser	Leu	Leu	Val	Ile	Leu	Pro	
			165						170					175		
Ile	Met	Ile	Tyr	Ala	Gly	Leu	Arg	Ser	Asn	Gln	Trp	Gly	Arg	Ser	Ser	
			180					185					190			
Cys	Thr	Ile	Asn	Trp	Pro	Gly	Glu	Ser	Gly	Ala	Trp	Tyr	Thr	Gly	Phe	
			195				200					205				
Ile	Ile	Tyr	Ala	Phe	Ile	Leu	Gly	Phe	Leu	Val	Pro	Leu	Thr	Ile	Ile	
			210				215				220					
Cys	Leu	Cys	Tyr	Leu	Arg	Ile	Ile	Ile	Lys	Val	Lys	Ser	Ser	Gly	Ile	
225					230					235					240	
Arg	Val	Gly	Ser	Ser	Lys	Arg	Lys	Lys	Ser	Glu	Lys	Lys	Val	Thr	Arg	
				245					250					255		
Met	Val	Ser	Ile	Val	Val	Ala	Val	Phe	Ile	Phe	Cys	Trp	Leu	Pro	Phe	
			260					265					270			
Tyr	Ile	Phe	Asn	Val	Ser	Ser	Val	Ser	Val	Ala	Ile	Ser	Pro	Thr	Pro	
			275				280					285				
Ala	Leu	Lys	Gly	Met	Phe	Asp	Phe	Val	Val	Ile	Leu	Thr	Tyr	Ala	Asn	
			290			295					300					
Ser	Cys	Ala	Asn	Pro	Ile	Leu	Tyr	Ala	Phe	Leu	Ser	Asp	Asn	Phe	Lys	
305					310					315					320	
Lys	Ser	Phe	Gln	Asn	Val	Leu	Cys	Leu	Val	Lys	Val	Ser	Gly	Ala	Glu	
				325					330					335		
Asp	Gly	Glu	Arg	Ser	Asp	Ser	Lys	Gln	Asp	Lys	Ser	Arg	Leu	Asn	Glu	
			340					345					350			
Thr	Thr	Glu	Thr	Gln	Arg	Thr	Leu	Leu	Asn	Gly	Asp	Leu	Gln	Thr	Ser	


355

360

365

Ile



CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below:	
<u>January 28, 2002</u> Date	 Gina N. Shishima

RECEIVE
FEB 28 2002
TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Yu

Serial No.: 09/841,720

Filed: April 24, 2001

For: MU OPIOID RECEPTOR METHODS (as amended)

Group Art Unit: 1647

Examiner: Unknown

Atty. Dkt. No.: INDA:002USD1

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE DISCLOSURES

BOX SEQUENCE

Commissioner for Patents
Washington, DC 20231

Commissioner:

This paper is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence Disclosures mailed October 26, 2001, for which the two month date for response was December 26, 2001. A Statement as Required Under 37 C.F.R. § 1.825(a) and (b) and Statement as Required Under 37 C.F.R. § 1.821(g) has been included herewith, including a computer readable form.

A request for a one-month extension of time to respond is included herewith along with the required fee. This one-month extension will bring the due date to January 28, 2002 (since January 26, 2002 falls on a weekend), which is within the six-month statutory period. Should such request or fee be deficient or absent, consider this paragraph such a request and

authorization to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10103856/GNS.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201
(512) 536-4598 (facsimile)

Date: January 28, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20503
www.uspto.gov

RECEIVED
FEB 28 2002
TECH. CENTER
FEB 16 2002

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/841,720	04/24/2001	Lei Yu	INDA:002USD1

Gina N. Shishima
FULBRIGHT & JAWORSKI L.L.P.
Suite 2400
600 Congress Avenue
Austin, TX 78701



CONFIRMATION NO. 6286

FORMALITIES LETTER



OC00000006972971

Date Mailed: 10/26/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202